CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below. Click here to see a list of People We’ve Funded. Click here to see a list of our Funded Institutions.
All CIRM Grants
Search Filters »
| Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
| City of Hope, Beckman Research Institute |
Dr. Angelo Manuel Almeida Cardoso Ph.D., MD |
Late Stage Preclinical Projects |
Ex Vivo Gene Engineering of Blood Stem Cells for Enhanced Chemotherapy Efficacy in Glioblastoma Patients |
$3,684,259 |
| University of California, Irvine |
Dr. Leslie M Thompson |
Late Stage Preclinical Projects |
An hESC-derived hNSC Therapeutic for Huntington’s Disease |
$5,635,393 |
| Fate Therapeutics, Inc. |
Bob Valamehr |
Late Stage Preclinical Projects |
IND enabling development of FT516: A Natural Killer Cell Immunotherapy for Cancer Derived from a Human Inducible Pluripotent Stem Cell |
$4,000,000 |
| Stanford University |
Dr. Matthew H Porteus |
Late Stage Preclinical Projects |
Genome Editing of Autologous Hematopoietic Stem Cells to Treat Sickle Cell Disease |
$4,849,363 |
| Cellerant Therapeutics, Inc. |
Swapna Panuganti |
Late Stage Preclinical Projects |
Development of CLT030-ADC, a Leukemic Stem Cell Targeting Antibody-Drug-Conjugate, for Treatment of Acute Myeloid Leukemia |
$6,863,755 |
| Cellular Biomedicine Group, Inc. |
Jack J. Wang |
Late Stage Preclinical Projects |
Allogenic human adipose-derived mesenchymal stem cells for the treatment of knee osteoarthritis |
$1,200,000 |
| Stanford University |
Dr. Gary Steinberg |
Late Stage Preclinical Projects |
Intraparenchymal NR1 Stem Cell Therapy for Chronic Subcortical Ischemic Stroke |
$5,300,000 |
| University of California, San Diego |
Dr. Stephanie Cherqui |
Late Stage Preclinical Projects |
Ex vivo transduced autologous human CD34+ hematopoietic stem cells for treatment of cystinosis |
$5,273,189 |
| University of California, Los Angeles |
Dr. Sophie X Deng |
Late Stage Preclinical Projects |
Regeneration of a Normal Corneal Surface by Limbal Stem Cell Therapy |
$4,244,211 |
| ViaCyte, Inc. |
Dr. Tim Kieffer |
Late Stage Preclinical Projects |
Stem cell-derived islet cell replacement therapy with immunosuppression for high-risk type 1 diabetes |
$3,544,721 |
| University of California, San Francisco |
Dr Jennifer M Puck |
Late Stage Preclinical Projects |
Ex Vivo Transduction of the Human Artemis (DCLRE1C) cDNA by Lentiviral Vector AProArt into CD34+ Hematopoietic Cells for Artemis (ART)-Deficient Severe Combined Immunodeficiency (SCID) |
$4,268,865 |
| Angiocrine Bioscience, Inc. |
Dr. Paul W Finnegan |
Late Stage Preclinical Projects |
Development of AB-110: genetically-modified endothelial cells plus expanded cord blood hematopoietic stem cells as a transplantation therapy |
$3,797,117 |
| Calibr |
Peter G Schultz |
Late Stage Preclinical Projects |
Development of a Chondrogenic Drug Candidate Targeting Resident Mesenchymal Stem Cells for the Treatment of Osteoarthritis |
$1,667,832 |
| Cedars-Sinai Medical Center |
Shaomei Wang |
Late Stage Preclinical Projects |
IND-enabling study of subretinal delivery of human neural progenitor cells for the treatment of retinitis pigmentosa |
$4,954,514 |
| Calibr |
Peter G Schultz |
Preclinical Development Awards |
Development of a Chondrogenic Drug Candidate Targeting Cartilage-residing Mesenchymal Stem Cells for the Treatment of Osteoarthritis |
$2,306,703 |
| Scripps Health |
Dr. Darryl D. D’Lima |
Preclinical Development Awards |
Embryonic Stem Cell-Derived Chondroprogenitor Cells to Repair Osteochondral Defects |
$7,660,211 |
| University of California, Davis |
Dr. Roslyn Rivkah Isseroff |
Preclinical Development Awards |
Scaffold for dermal regeneration containing pre-conditioned mesenchymal stem cells to heal chronic diabetic wounds |
$4,620,144 |
| University of California, Irvine |
Dr. Leslie M Thompson |
Preclinical Development Awards |
A hNSC Development Candidate for Huntington’s Disease |
$4,951,623 |
| Stanford University |
Dr. Matthew H Porteus |
Preclinical Development Awards |
Pre-clinical development of gene correction therapy of hematopoietic stem cells for SCID-X1 |
$874,877 |
| University of California, Davis |
Dr. Diana L. Farmer |
Preclinical Development Awards |
Placental Stem Cells for the In Utero Treatment of Spina Bifida |
$2,182,146 |
| Salk Institute for Biological Studies |
Dr. David R Schubert |
Preclinical Development Awards |
Human Stem-Cell Based Development of a Potent Alzheimer’s Drug Candidate |
$1,664,885 |
| ViaCyte, Inc. |
Howard Foyt |
Accelerated Development Pathway I |
Clinical Development of a Cell Therapy for Diabetes |
$8,783,852 |
| University of California, San Diego |
Catriona Jamieson |
Alpha Stem Cell Clinics |
Alpha Stem Cell Clinic for the Development of Regenerative Therapies |
$8,679,137 |
| University of California, Los Angeles |
John S. Adams |
Alpha Stem Cell Clinics |
UCLA-UCI Alpha Stem Cell Clinic (ASCC) Consortium |
$8,680,000 |
| City of Hope, Beckman Research Institute |
Prof. John A. Zaia |
Alpha Stem Cell Clinics |
The Innovation-Alpha Clinic for Cellular Therapies (I-ACT) – A Program for the Development and Delivery of Innovative Cell-based Treatments and Cures for Life-threatening Diseases. |
$8,416,531 |
| University of California, Davis |
Dr. J. Kent Leach |
Tools and Technologies III |
Multi-modal technology for non-destructive characterization of bioengineered tissues |
$1,574,151 |
| University of Southern California |
Dr. Qilong Ying |
Tools and Technologies III |
Embryonic stem cell-based generation of rat models for assessing human cellular therapies |
$1,326,979 |
| Stanford University |
Sarah Heilshorn |
Tools and Technologies III |
Injectable Hydrogels for the Delivery, Maturation, and Engraftment of Clinically Relevant Numbers of Human Induced Pluripotent Stem Cell-Derived Neural Progenitors to the Central Nervous System |
$1,347,767 |
| Stanford University |
Dr. James C. Dunn Dr. |
Tools and Technologies III |
Skin-derived precursor cells for the treatment of enteric neuromuscular dysfunction |
$772,098 |
| University of California, Los Angeles |
Dr. James C. Dunn Dr. |
Tools and Technologies III |
Skin-derived precursor cells for the treatment of enteric neuromuscular dysfunction |
$1,044,423 |
| University of California, San Diego |
Dr. Shyni Varghese |
Tools and Technologies III |
Technologies to improve in vivo function of transplanted stem cells |
$1,373,683 |
| University of California, San Diego |
Shaochen Chen |
Tools and Technologies III |
Development of 3D Bioprinting Techniques using Human Embryonic Stem Cells Derived Cardiomyocytes for Cardiac Tissue Engineering |
$1,368,264 |
| University of California, Irvine |
Dr. Mathew Mark Blurton-Jones |
Tools and Technologies III |
Optimizing the differentiation and expansion of microglial progenitors from human pluripotent stem cells for the study and treatment of neurological disease. |
$1,147,596 |
| University of California, Davis |
Dr. Laura Marcu |
Tools and Technologies III |
Multimodal platform combining optical and ultrasonic technologies for in vivo nondestructive evaluation of engineered vascular tissue constructs |
$1,834,350 |
| University of Southern California |
Dr. Paula M. Cannon |
Tools and Technologies III |
Site-specific gene editing in hematopoietic stem cells as an anti-HIV therapy |
$1,495,665 |
| City of Hope, Beckman Research Institute |
Joseph D Gold |
Tools and Technologies III |
Development of a scalable, practical, and transferable GMP-compliant suspension culture-based differentiation process for cardiomyocyte production from human embryonic stem cells. |
$891,518 |
| Stanford University |
Dr. Fan Yang PhD |
Tools and Technologies III |
Injectable Macroporous Matrices to Enhance Stem Cell Engraftment and Survival |
$1,434,235 |
| University of California, Berkeley |
Dr. David V. Schaffer |
Tools and Technologies III |
Engineered Biomaterials for Scalable Manufacturing and High Viability Implantation of hPSC-Derived Cells to Treat Neurodegenerative Disease |
$1,239,276 |
| Stanford University |
Dr. Joseph C. Wu |
Tools and Technologies III |
Macaca mulatta as advanced model for predictive preclinical testing of engineered cardiac autografts and allografts |
$1,689,744 |
| Stanford University |
Dr. Anthony E. Oro |
Tools and Technologies III |
A Chromatin Context Tool for Predicting iPS Lineage Predisposition and Tissue Graftability |
$1,391,125 |
| University of California, Los Angeles |
Dr. Hanna Mikkola |
Tools and Technologies III |
A suite of engineered human pluripotent stem cell lines to facilitate the generation of hematopoietic stem cells |
$1,382,400 |
| University of California, San Francisco |
Dr. Andrew D. Leavitt MD |
Tools and Technologies III |
Small molecule tools and scale-up technologies to expand human umbilical cord blood stem and progenitor cells for clinical and research use |
$1,416,600 |
| Stanford University |
Professor Irving L Weissman MD |
Tools and Technologies III |
Identification and isolation of transplantable human hematopoietic stem cells from pluripotent cell lines; two steps from primitive hematopoiesis to transplantable definitive cells, and non-toxic conditioning of hosts for hematopoeitic stem cell transp… |
$1,271,952 |
| University of California, Los Angeles |
Dr. Carla M. Koehler |
Tools and Technologies III |
A small molecule tool for reducing the malignant potential in reprogramming human iPSCs and ESCs |
$1,283,900 |
| University of Southern California |
Dr. Toshio Miki |
Tools and Technologies III |
Development of a clinical-grade extracorporeal liver support system using human induced pluripotent stem cell-derived hepatic cells |
$1,257,011 |
| Scripps Research Institute |
Dr. Jeanne F Loring |
Tools and Technologies III |
User-friendly predictive molecular diagnostic assays for quality control of stem cell derivatives for transplantation and drug discovery |
$1,728,390 |
| University of California, Los Angeles |
Leif Havton |
Tools and Technologies III |
Development of a Relevant Pre-Clinical Animal Model as a Tool to Evaluate Human Stem Cell-Derived Replacement Therapies for Motor Neuron Injuries and Degenerative Diseases |
$1,308,711 |
| University of California, Davis |
Randi Hagerman |
Conference |
Pathways of Neurodevelopmental Disorders (C8) |
$29,939 |
| Stanford University |
Dr. Joseph C. Wu |
Conference |
Cardiovascular Tissue Engineering Symposium |
$25,000 |
| Ocular Research Symposia Foundation, Inc. |
Dr. Gerald Chader |
Conference |
SIGHT RESTORATION THROUGH STEM CELL THERAPY |
$20,000 |
